BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24696288)

  • 1. Stereotactic gamma-ray body radiation therapy for asynchronous bilateral renal cell carcinoma.
    Wang YJ; Han TT; Xue JX; Chang DS; Li HQ; Li P; Wang JD; Wang YJ; Xia TY
    Radiol Med; 2014 Nov; 119(11):878-83. PubMed ID: 24696288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
    Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture.
    Thibault I; Al-Omair A; Masucci GL; Masson-Côté L; Lochray F; Korol R; Cheng L; Xu W; Yee A; Fehlings MG; Bjarnason GA; Sahgal A
    J Neurosurg Spine; 2014 Nov; 21(5):711-8. PubMed ID: 25170656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?
    Amini A; Altoos B; Bourlon MT; Bedrick E; Bhatia S; Kessler ER; Flaig TW; Fisher CM; Kavanagh BD; Lam ET; Karam SD
    Pract Radiat Oncol; 2015; 5(6):e589-e596. PubMed ID: 26142027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma.
    Ponsky L; Lo SS; Zhang Y; Schluchter M; Liu Y; Patel R; Abouassaly R; Welford S; Gulani V; Haaga JR; Machtay M; Ellis RJ
    Radiother Oncol; 2015 Oct; 117(1):183-7. PubMed ID: 26362723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity.
    Pham D; Thompson A; Kron T; Foroudi F; Kolsky MS; Devereux T; Lim A; Siva S
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1061-8. PubMed ID: 25442039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-fraction versus multifraction spinal stereotactic radiosurgery for spinal metastases from renal cell carcinoma: secondary analysis of Phase I/II trials.
    Ghia AJ; Chang EL; Bishop AJ; Pan HY; Boehling NS; Amini B; Allen PK; Li J; Rhines LD; Tannir NM; Tatsui CE; Brown PD; Yang JN
    J Neurosurg Spine; 2016 May; 24(5):829-36. PubMed ID: 26799117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control.
    Stinauer MA; Kavanagh BD; Schefter TE; Gonzalez R; Flaig T; Lewis K; Robinson W; Chidel M; Glode M; Raben D
    Radiat Oncol; 2011 Apr; 6():34. PubMed ID: 21477295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal cell carcinoma treated with stereotactic radiotherapy with histological change confirmed on autopsy: a case report.
    Onishi H; Kawasaki T; Zakoji H; Yoshida T; Komiyama T; Kuriyama K; Araya M; Saito R; Aoki S; Maehata Y; Tominaga L; Marino K; Watanabe I; Oguri M; Araki T; Enomoto N; Takeda M; Katoh R
    BMC Res Notes; 2014 Apr; 7():270. PubMed ID: 24767701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic Ablative Radiotherapy (SABR) for Large Renal Tumors: A Retrospective Case Series Evaluating Clinical Outcomes, Toxicity, and Technical Considerations.
    Correa RJM; Rodrigues GB; Chen H; Warner A; Ahmad B; Louie AV
    Am J Clin Oncol; 2018 Jun; 41(6):568-575. PubMed ID: 27635623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma.
    Ranck MC; Golden DW; Corbin KS; Hasselle MD; Liauw SL; Stadler WM; Hahn OM; Weichselbaum RR; Salama JK
    Am J Clin Oncol; 2013 Dec; 36(6):589-95. PubMed ID: 22868242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma.
    Yamamoto T; Kadoya N; Takeda K; Matsushita H; Umezawa R; Sato K; Kubozono M; Ito K; Ishikawa Y; Kozumi M; Takahashi N; Katagiri Y; Onishi H; Jingu K
    Radiat Oncol; 2016 May; 11():72. PubMed ID: 27229710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal Cancer is Not Radioresistant: Slowly but Continuing Shrinkage of the Tumor After Stereotactic Body Radiation Therapy.
    Funayama S; Onishi H; Kuriyama K; Komiyama T; Marino K; Araya M; Saito R; Aoki S; Maehata Y; Nonaka H; Tominaga L; Muramatsu J; Nakagomi H; Kamiyama M; Takeda M
    Technol Cancer Res Treat; 2019 Jan; 18():1533033818822329. PubMed ID: 30803362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).
    Scorsetti M; Comito T; Cozzi L; Clerici E; Tozzi A; Franzese C; Navarria P; Fogliata A; Tomatis S; D'Agostino G; Iftode C; Mancosu P; Ceriani R; Torzilli G
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1301-9. PubMed ID: 25644863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiation therapy for benign spine tumors: is dose de-escalation appropriate?
    Kalash R; Glaser SM; Flickinger JC; Burton S; Heron DE; Gerszten PC; Engh JA; Amankulor NM; Vargo JA
    J Neurosurg Spine; 2018 Aug; 29(2):220-225. PubMed ID: 29799334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy.
    Rwigema JC; Heron DE; Ferris RL; Andrade RS; Gibson MK; Yang Y; Ozhasoglu C; Argiris AE; Grandis JR; Burton SA
    Am J Clin Oncol; 2011 Aug; 34(4):372-9. PubMed ID: 20859194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiotherapy for inoperable patients with renal carcinoma.
    Kotzki L; Udrescu C; Lapierre A; Badet L; Rouviere O; Paparel P; Chapet O
    Fr J Urol; 2024 Mar; 34(2):102575. PubMed ID: 38364353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When Surgery Is Not an Option in Renal Cell Carcinoma: The Evolving Role of Stereotactic Body Radiation Therapy.
    Miccio J; Johung K
    Oncology (Williston Park); 2019 May; 33(5):167-73, 177. PubMed ID: 31095714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer.
    Xia T; Li H; Sun Q; Wang Y; Fan N; Yu Y; Li P; Chang JY
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):117-25. PubMed ID: 16765528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.
    Angelov L; Mohammadi AM; Bennett EE; Abbassy M; Elson P; Chao ST; Montgomery JS; Habboub G; Vogelbaum MA; Suh JH; Murphy ES; Ahluwalia MS; Nagel SJ; Barnett GH
    J Neurosurg; 2018 Aug; 129(2):366-382. PubMed ID: 28937324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.